false2022-12-31Q20001075880--06-30 0001075880 2022-07-01 2022-12-31 0001075880 2021-07-01 2021-12-31 0001075880 2022-12-31 0001075880 2022-06-30 0001075880 2022-01-01 2022-06-30 0001075880 2021-06-30 0001075880 2021-12-31 0001075880 ifrs-full:IssuedCapitalMember 2022-07-01 2022-12-31 0001075880 ifrs-full:OtherEquityInterestMember 2022-07-01 2022-12-31 0001075880 ifrs-full:OtherReservesMember 2022-07-01 2022-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2022-07-01 2022-12-31 0001075880 ifrs-full:RetainedEarningsMember 2022-07-01 2022-12-31 0001075880 kzia:UnlistedOptionsMember 2022-07-01 2022-12-31 0001075880 kzia:EVT801LicensingAgreementMember 2022-07-01 2022-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberEightMember kzia:IssueDateSevenJulyTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberNineMember kzia:IssueDateEightAugustTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberTenMember kzia:IssueDateNineAugustTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberElevenMember kzia:IssueDateTenAugustTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberTwelveMember kzia:IssueDateElevenAugustTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberThirteenMember kzia:IssueDateTwelveAugustTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberFourteenMember kzia:IssueDateTwelveSeptemberTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberFifteenMember kzia:IssueDateThirteenSeptemberTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:ScientificAdvisoryBoardIssueMember kzia:IssueDateFourteenSeptemberTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberSixteenMember kzia:IssueDateSevenOctoberTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:AtmIssueOfSharesNumberSeventeenMember kzia:IssueDateTwentyEightOctoberTwoThousandAndTwentyTwoMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:ShareIssueTransactionCostsMember 2022-07-01 2022-12-31 0001075880 kzia:AmericanDepositorySharesMember kzia:AtTheMarketEquityProgramMember 2022-07-01 2022-12-31 0001075880 ifrs-full:ContingentConsiderationMember 2022-07-01 2022-12-31 0001075880 kzia:MilestoneTwoMember 2022-07-01 2022-12-31 0001075880 kzia:GenentechAgreementMember 2022-07-01 2022-12-31 0001075880 kzia:GlioblastPtyLtdMember 2022-07-01 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember 2021-07-01 2021-12-31 0001075880 ifrs-full:OtherEquityInterestMember 2021-07-01 2021-12-31 0001075880 ifrs-full:OtherReservesMember 2021-07-01 2021-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2021-07-01 2021-12-31 0001075880 ifrs-full:RetainedEarningsMember 2021-07-01 2021-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember 2021-07-01 2021-12-31 0001075880 kzia:EVT801LicensingAgreementMember 2021-07-01 2021-12-31 0001075880 ifrs-full:PreviouslyStatedMember 2021-07-01 2021-12-31 0001075880 ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember 2021-07-01 2021-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember ifrs-full:AccumulatedDepreciationAndAmortisationMember 2022-12-31 0001075880 ifrs-full:AccumulatedDepreciationAndAmortisationMember kzia:EVT801LicensingAgreementMember 2022-12-31 0001075880 kzia:EVT801LicensingAgreementMember 2022-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember ifrs-full:GrossCarryingAmountMember ifrs-full:AtFairValueMember 2022-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember 2022-12-31 0001075880 ifrs-full:GrossCarryingAmountMember ifrs-full:AtCostMember kzia:EVT801LicensingAgreementMember 2022-12-31 0001075880 kzia:GstRefundableMember 2022-12-31 0001075880 kzia:PaxalisibphaseIiClinicalTrialRefundMember 2022-12-31 0001075880 kzia:RefundableMember 2022-12-31 0001075880 kzia:DepositsPaidMember 2022-12-31 0001075880 kzia:ContingentConsiderationPaxalisibMember 2022-12-31 0001075880 kzia:ContingentConsiderationEvt801Member 2022-12-31 0001075880 kzia:GbmAgileDepositMember 2022-12-31 0001075880 kzia:CorporateCreditCardDepositMember 2022-12-31 0001075880 kzia:InsurancePremiumFundingMember 2022-12-31 0001075880 kzia:PaxalisibLicensingAgreementMember ifrs-full:AccumulatedDepreciationAndAmortisationMember 2022-06-30 0001075880 ifrs-full:AccumulatedDepreciationAndAmortisationMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 kzia:PaxalisibLicensingAgreementMember ifrs-full:GrossCarryingAmountMember ifrs-full:AtFairValueMember 2022-06-30 0001075880 kzia:PaxalisibLicensingAgreementMember 2022-06-30 0001075880 ifrs-full:GrossCarryingAmountMember ifrs-full:AtCostMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 kzia:GstRefundableMember 2022-06-30 0001075880 kzia:PaxalisibphaseIiClinicalTrialRefundMember 2022-06-30 0001075880 kzia:RefundableMember 2022-06-30 0001075880 kzia:DepositsPaidMember 2022-06-30 0001075880 kzia:ContingentConsiderationPaxalisibMember 2022-06-30 0001075880 kzia:ContingentConsiderationEvt801Member 2022-06-30 0001075880 kzia:GbmAgileDepositMember 2022-06-30 0001075880 kzia:CorporateCreditCardDepositMember 2022-06-30 0001075880 ifrs-full:GrossCarryingAmountMember kzia:EVT801LicensingAgreementMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember ifrs-full:GrossCarryingAmountMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 ifrs-full:GrossCarryingAmountMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 ifrs-full:AccumulatedDepreciationAndAmortisationMember kzia:EVT801LicensingAgreementMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember ifrs-full:AccumulatedDepreciationAndAmortisationMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 kzia:EVT801LicensingAgreementMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember kzia:EVT801LicensingAgreementMember 2022-06-30 0001075880 kzia:ContingentConsiderationEvt801Member ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 kzia:ContingentConsiderationEvt801Member ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember 2022-06-30 0001075880 ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember 2022-06-30 0001075880 kzia:InsurancePremiumFundingMember 2022-06-30 0001075880 kzia:AtTheMarketEquityProgramMember 2022-05-01 0001075880 kzia:AmericanDepositorySharesMember kzia:AtTheMarketEquityProgramMember 2022-05-01 0001075880 kzia:LabcorpEarlyDevelopmentLaboratoriesIncMember kzia:DepositRecievedMember 2023-01-03 0001075880 ifrs-full:MajorOrdinaryShareTransactionsMember kzia:SharePurchasePlanMember kzia:ConditionalPlacementMember 2023-01-16 2023-01-16 0001075880 ifrs-full:MajorOrdinaryShareTransactionsMember kzia:SharePurchasePlanMember 2023-01-16 2023-01-16 0001075880 ifrs-full:MajorOrdinaryShareTransactionsMember kzia:SharePurchasePlanMember kzia:UnconditionalPlacementMember 2023-01-16 2023-01-16 0001075880 ifrs-full:MajorOrdinaryShareTransactionsMember kzia:SharePurchasePlanMember kzia:UnconditionalPlacementMember 2023-01-16 0001075880 ifrs-full:MajorOrdinaryShareTransactionsMember kzia:SharePurchasePlanMember kzia:ConditionalPlacementMember 2023-01-16 0001075880 kzia:SharePurchasePlanMember ifrs-full:TopOfRangeMember ifrs-full:MajorOrdinaryShareTransactionsMember 2023-01-16 0001075880 kzia:AtmIssueOfSharesNumberEightMember 2022-07-07 2022-07-07 0001075880 kzia:AtmIssueOfSharesNumberNineMember 2022-08-08 2022-08-08 0001075880 kzia:AtmIssueOfSharesNumberTenMember 2022-08-09 2022-08-09 0001075880 kzia:AtmIssueOfSharesNumberElevenMember 2022-08-10 2022-08-10 0001075880 kzia:AtmIssueOfSharesNumberTwelveMember 2022-08-11 2022-08-11 0001075880 kzia:AtmIssueOfSharesNumberThirteenMember 2022-08-12 2022-08-12 0001075880 kzia:AtmIssueOfSharesNumberFourteenMember 2022-09-12 2022-09-12 0001075880 kzia:AtmIssueOfSharesNumberFifteenMember 2022-09-13 2022-09-13 0001075880 kzia:ScientificAdvisoryBoardIssueMember 2022-09-14 2022-09-14 0001075880 kzia:AtmIssueOfSharesNumberSixteenMember 2022-10-07 2022-10-07 0001075880 kzia:AtmIssueOfSharesNumberSeventeenMember 2022-10-28 2022-10-28 0001075880 kzia:ShareIssueTransactionCostsMember 2022-12-31 2022-12-31 0001075880 kzia:EVT801LicensingAgreementMember 2022-01-01 2022-06-30 0001075880 ifrs-full:ContingentConsiderationMember 2022-01-01 2022-06-30 0001075880 kzia:GlioblastPtyLtdMember 2017-06-30 0001075880 ifrs-full:IssuedCapitalMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:OtherEquityInterestMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:OtherReservesMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:RetainedEarningsMember ifrs-full:PreviouslyStatedMember 2022-06-30 0001075880 ifrs-full:IssuedCapitalMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 ifrs-full:OtherEquityInterestMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 ifrs-full:OtherReservesMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 ifrs-full:RetainedEarningsMember ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2022-06-30 0001075880 ifrs-full:IssuedCapitalMember 2022-06-30 0001075880 ifrs-full:OtherEquityInterestMember 2022-06-30 0001075880 ifrs-full:OtherReservesMember 2022-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2022-06-30 0001075880 ifrs-full:RetainedEarningsMember 2022-06-30 0001075880 ifrs-full:IssuedCapitalMember 2022-12-31 0001075880 kzia:IssuedCapitalExcludingIssuanceCostMember 2022-06-30 0001075880 kzia:IssuedCapitalExcludingIssuanceCostMember 2022-12-31 0001075880 ifrs-full:OtherEquityInterestMember 2022-12-31 0001075880 ifrs-full:OtherReservesMember 2022-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2022-12-31 0001075880 ifrs-full:RetainedEarningsMember 2022-12-31 0001075880 ifrs-full:IssuedCapitalMember ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 ifrs-full:OtherEquityInterestMember ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 ifrs-full:OtherReservesMember ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 ifrs-full:RetainedEarningsMember ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 ifrs-full:PreviouslyStatedMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember ifrs-full:IssuedCapitalMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember ifrs-full:OtherEquityInterestMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember ifrs-full:OtherReservesMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember kzia:ForeignCurrencyTranslationReserveMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember ifrs-full:RetainedEarningsMember 2021-06-30 0001075880 ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember 2021-06-30 0001075880 ifrs-full:IssuedCapitalMember 2021-06-30 0001075880 ifrs-full:OtherEquityInterestMember 2021-06-30 0001075880 ifrs-full:OtherReservesMember 2021-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2021-06-30 0001075880 ifrs-full:RetainedEarningsMember 2021-06-30 0001075880 ifrs-full:IssuedCapitalMember 2021-12-31 0001075880 ifrs-full:OtherEquityInterestMember 2021-12-31 0001075880 ifrs-full:OtherReservesMember 2021-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2021-12-31 0001075880 ifrs-full:RetainedEarningsMember 2021-12-31 iso4217:AUD xbrli:shares iso4217:USD xbrli:pure iso4217:EUR iso4217:AUD xbrli:shares kzia:Milestone
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Form 6-K/A
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2023
Commission File Number 000-29962
 
 
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
 
 
Three International Towers Level 24 300 Barangaroo Avenue Sydney
NSW
2000
(Address of principal executive office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F
or
Form 40-F.
Form 20-F  ☑             Form 40-F   ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
 
 
 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

This Amendment No. 1 to the 6-K of Kazia Therapeutics Limited (the “Company”) that was filed with the Securities and Exchange Commission on February 28, 2023 is being filed solely to include interactive data files in inline eXtensible Business Reporting Language (iXBRL) in connection with the Company’s interim results for the half-year ended December 31, 2022.

Attached as Exhibit 99.1 of this Report on Form 6-K is a copy of the Company’s interim results for the half-year ended December 31, 2022, which are hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-259224).

EXHIBIT LIST

 

Exhibit

   

Description

99.1    Half-year report for the six months ended December 31, 2022
101.INS    XBRL Instance Document
101.SCH    XBRL Taxonomy Extension Schema Document
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    XBRL Taxonomy Extension Label Linkbase Document
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ Karen Krumeich

Karen Krumeich

Chief Financial Officer

Date: 9 March 2023

Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Kazia Therapeutics Charts.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Kazia Therapeutics Charts.